Ocular Therapeutix to file eye drug
This article was originally published in Scrip
Executive Summary
Massachusetts-based Ocular Therapeutix is set to file for US approval of its sustained-release dexamethasone product OTX-DP in the second quarter, following positive top-line data from the first of two Phase III trials in post-surgical ocular pain and inflammation. The company says that the ability to administer the entire course of therapy for post-operative inflammation and pain with a single dose would "remove the onus from patients to follow complex pharmaceutical dosing regimens while providing the desired tapered therapeutic effect". OTX-DP is placed in the canaliculus and designed to deliver dexamethasone to the ocular surface for about four weeks. The product resorbs and exits the nasolacrimal system without need for removal. The 247-patient study met both its efficacy endpoints, significantly improving pain and reducing the presence of inflammatory cells in the anterior chamber of the eye compared with placebo. Safety finding are still being analysed, and data from the second Phase III study are due by the end of the month.
You may also be interested in...
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.